Keyword: Axovant Sciences
Rachelle Jacques, who most recently was a senior vice president at Alexion, takes over from Alvin Shih, M.D., who signed on at Enzyvant in November 2016.
Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.
Axovant spun off its small molecule team into Arvelle Therapeutics, as it continues its march toward a sole focus on gene therapies.
Axovant Sciences has renamed itself Axovant Gene Therapies to put a seal on its bid to become a player at the cutting edge of genetic medicine.
Since Pavan Cheruvu took Axovant’s helm in February 2018, the company has been plugging away at becoming a gene therapy player.
The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two assets that are in or near the clinic.
Axovant has halted development of nelotanserin after it missed the primary endpoint in a phase 2 trial in patients with Lewy body dementia.
Abeona fires CEO Carsten Thiel; MHRA CEO to leave in wake of Brexit; Lilly CMO to lead Brickell Bio; and Janssen's discovery head joins Incyte.
After refocusing on gene therapy, Axovant is appointing five new executives to posts ranging from clinical development to commercial operations.
The gene therapy suppresses expression of a mutated protein and encourages production of a functional version, thereby lessening muscular problems.
